According to the head of Roche’s pharmaceuticals division, takeovers in the pharmaceutical and biotech sectors are again possible at reasonably reasonable prices. “These are not bargains,” said Bill Anderson to investors in the Basel drug manufacturer in London. “But we’re able to find transactions at a reasonable price and partner.” In 2021, on the other hand, prices would have gone crazy, and Roche had therefore held back with acquisitions. Only two deals were closed in 2021, compared to nine in the previous year and eight in 2019. There have been five transactions so far this year. “So we’re pretty much back on track to our historical average,” said the manager. Anderson reiterated that Roche will continue to invest heavily in research and development (R&D). Last year, twelve billion Swiss francs or around a quarter of the division’s sales flowed into the development of new drugs.
Pharmaceutical industry – Roche buys again – economy
